Optical News

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t...

DURHAM, N.C.--(BUSINESS WIRE)--Sightview will offer early demo access to its new flagship EHR platform at the 2026 ASCRS Annual Meeting....

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences. Piper Sandler Biopharma Symposium 1x1 Meetings: Wednesday, April 15, 2026 Location: Boston, MA UBS Private Biotech Summit 1x1 Meetings: Monday, May 18, 2026 Location: New York, NY About Ollin Biosciences Established...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to be the first...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to t...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of it...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026. Cash position as of March 31, 2026 GenSight Biologics’ cash and cash equivalents totaled €3.2 million...

TORONTO--(BUSINESS WIRE)--This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. For the estimated 8.5 million Canadians living with dry eye, symptoms such as stinging, burning, tired, irritated and watery eyes can appear during everyday activi...

CAESAREA, Israel--(BUSINESS WIRE)--ForSight Robotics, the global pioneer in robotic eye surgery, today announced the successful completion of the world’s first fully robot-assisted cataract surgery performed in a human patient using its proprietary JASPER™ Platform. The landmark breakthrough introduces a new era of robotic precision in the most commonly performed surgical procedure in medicine, fundamentally reshaping ophthalmic care. The procedure was performed with the JASPER™ Platform by Dr....